Shares of Aptevo Therapeutics Inc (NASDAQ:APVO) were up 12.2% during mid-day trading on Monday after an insider bought additional shares in the company. The company traded as high as $4.50 and last traded at $4.23. Approximately 985,600 shares were traded during mid-day trading, an increase of 187% from the average daily volume of 342,962 shares. The stock had previously closed at $3.77.
Specifically, VP Randy Joe Maddux purchased 25,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was bought at an average cost of $2.76 per share, with a total value of $69,000.00. Following the acquisition, the vice president now directly owns 25,000 shares of the company’s stock, valued at $69,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.60% of the stock is owned by insiders.
A number of analysts have issued reports on APVO shares. ValuEngine raised Aptevo Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $6.00 price target on shares of Aptevo Therapeutics in a report on Thursday, October 5th.
The company has a current ratio of 7.76, a quick ratio of 7.67 and a debt-to-equity ratio of 0.19.
Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its holdings in shares of Aptevo Therapeutics by 8.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock valued at $2,187,000 after purchasing an additional 78,109 shares during the last quarter. Precept Management LLC purchased a new stake in shares of Aptevo Therapeutics in the 2nd quarter valued at about $1,210,000. Legal & General Group Plc lifted its holdings in shares of Aptevo Therapeutics by 11,751.3% in the 2nd quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock valued at $815,000 after purchasing an additional 390,379 shares during the last quarter. Finally, Spark Investment Management LLC lifted its holdings in shares of Aptevo Therapeutics by 167.4% in the 2nd quarter. Spark Investment Management LLC now owns 61,500 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 38,500 shares during the last quarter. 32.22% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/11/aptevo-therapeutics-apvo-trading-up-12-2-after-insider-buying-activity.html.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.